Join to access to all OVN content. Join for Free
Important TIPS for KOL Mapping
KOL mapping key opinion leaders cross-functional coordination outreach methods Medical Science Liaison

Important TIPS for KOL Mapping


Share This Article


Summary

In this episode, Keely Dahl shares her expertise on KOL mapping, offering valuable insights into identifying and ranking key opinion leaders. She outlines the importance of cross-functional coordination in engaging with KOLs and provides strategies for acquiring meetings and optimizing contact lists. Keely discusses effective outreach methods, including email and phone communication, and emphasizes the significance of networking at conferences. The episode concludes with best practices for email communication and essential advice for MSLs aiming to enhance their KOL mapping skills.

Keely Dahl, Sr Medical Science Liaison at Aurinia Pharmaceuticals shares important tips for KOL mapping based on her real life experience

Keely shares…

πŸ‘‰ What is KOL Mapping and how to build your list

πŸ‘‰ Best ways to coordinate with cross functional partners

πŸ‘‰ Unique ways to engage with KOLs and gain better access

πŸ‘‰ How to maintain and prioritize your list

πŸ‘‰ Advice for closing out the year on a strong note

Click for Source
KOL mapping, key opinion leaders, cross-functional coordination, outreach methods, Medical Science Liaison

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN